SECAUCUS, N.J., Oct. 21, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.
"We delivered another quarter of robust top- and bottom-line growth, underscoring strong demand for our clinical solutions and diligent execution of our strategy," said Jim Davis, Chairman, CEO and President. "Revenues grew 13.1%, including 6.8% organic growth, driven by broad-based adoption of our clinical innovations, contributions from acquisitions, and growth in our consumer channel as we build our presence as the preferred lab engine inside top health and wellness brands. We also announced an agreement with Corewell Health to create a major lab services joint venture serving the state of Michigan. In addition, we will deploy our comprehensive Co-Lab Solutions across Corewell's nearly two dozen hospitals. Given our strong performance year-to-date, we are again raising our full year 2025 guidance."
Recent highlights:
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2025 | 2024 | Change | 2025 | 2024 | Change | |||||||
(dollars in millions, except per share data) | ||||||||||||
Reported: | ||||||||||||
Net revenues | $ 2,816 | $ 2,488 | 13.1 % | $ 8,229 | $ 7,251 | 13.5 % | ||||||
Diagnostic Information Services revenues | $ 2,755 | $ 2,427 | 13.5 % | $ 8,043 | $ 7,058 | 14.0 % | ||||||
Revenue per requisition | 0.8 % | 0.2 % | ||||||||||
Requisition volume | 12.5 % | 13.8 % | ||||||||||
Organic requisition volume | 3.9 % | 1.8 % | ||||||||||
Operating income (a) | $ 386 | $ 330 | 16.8 % | $ 1,170 | $ 985 | 18.7 % | ||||||
Operating income as a percentage of net revenues (a) | 13.7 % | 13.3 % | 0.4 % | 14.2 % | 13.6 % | 0.6 % | ||||||
Net income attributable to Quest Diagnostics (a) | $ 245 | $ 226 | 8.5 % | $ 747 | $ 649 | 15.0 % | ||||||
Diluted EPS (a) | $ 2.16 | $ 1.99 | 8.5 % | $ 6.57 | $ 5.74 | 14.5 % | ||||||
Cash provided by operations | $ 563 | $ 356 | 57.4 % | $ 1,421 | $ 870 | 63.1 % | ||||||
Capital expenditures | $ 144 | $ 106 | 37.0 % | $ 369 | $ 302 | 22.3 % | ||||||
Adjusted (a): | ||||||||||||
Operating income | $ 458 | $ 385 | 18.9 % | $ 1,330 | $ 1,132 | 17.5 % | ||||||
Operating income as a percentage of net revenues | 16.3 % | 15.5 % | 0.8 % | 16.2 % | 15.6 % | 0.6 % | ||||||
Net income attributable to Quest Diagnostics | $ 296 | $ 262 | 13.1 % | $ 845 | $ 758 | 11.5 % | ||||||
Diluted EPS | $ 2.60 | $ 2.30 | 13.0 % | $ 7.43 | $ 6.70 | 10.9 % | ||||||
(a) | For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below. |
Updated Guidance for Full Year 2025
The company updates its full year 2025 guidance as follows:
Updated Guidance | Prior Guidance | ||||||
Low | High | Low | High | ||||
Net revenues | $10.96 billion | $11.00 billion | $10.80 billion | $10.92 billion | |||
Net revenues increase | 11.0 % | 11.4 % | 9.4 % | 10.6 % | |||
Reported diluted EPS | $8.58 | $8.66 | $8.60 | $8.80 | |||
Adjusted diluted EPS | $9.76 | $9.84 | $9.63 | $9.83 | |||
Cash provided by operations | Approximately $1.8 billion | Approximately $1.55 billion | |||||
Capital expenditures | Approximately $500 million | Approximately $500 million | |||||
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, impairment charges and other items.
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on October 21, 2025 until midnight Eastern Time on November 4, 2025, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Operations For the Three and Nine Months Ended September 30, 2025 and 2024 (in millions, except per share data) (unaudited) | |||||||
Three Months Ended | Nine Months Ended | ||||||
2025 | 2024 | 2025 | 2024 | ||||
Net revenues | $ 2,816 | $ 2,488 | $ 8,229 | $ 7,251 | |||
Operating costs and expenses and other operating income: | |||||||
Cost of services | 1,867 | 1,677 | 5,474 | 4,865 | |||
Selling, general and administrative | 501 | 448 | 1,463 | 1,304 | |||
Amortization of intangible assets | 39 | 32 | 117 | 90 | |||
Other operating expense, net | 23 | 1 | 5 | 7 | |||
Total operating costs and expenses, net | 2,430 | 2,158 | 7,059 | 6,266 | |||
Operating income | 386 | 330 | 1,170 | 985 | |||
Other income (expense): | |||||||
Interest expense, net | (66) | (49) | (200) | (136) | |||
Other income, net | 8 | 15 | 18 | 27 | |||
Total non-operating expense, net | (58) | (34) | (182) | (109) | |||
Income before income taxes and equity in earnings of equity method investees | 328 | 296 | 988 | 876 | |||
Income tax expense | (77) | (65) | (233) | (205) | |||
Equity in earnings of equity method investees, net of taxes | 8 | 6 | 35 | 14 | |||
Net income | 259 | 237 | 790 | 685 | |||
Less: Net income attributable to noncontrolling interests | 14 | 11 | 43 | 36 | |||
Net income attributable to Quest Diagnostics | $ 245 | $ 226 | $ 747 | $ 649 | |||
Earnings per share attributable to Quest Diagnostics' common stockholders: | |||||||
Basic | $ 2.18 | $ 2.01 | $ 6.66 | $ 5.80 | |||
Diluted | $ 2.16 | $ 1.99 | $ 6.57 | $ 5.74 | |||
Weighted average common shares outstanding: | |||||||
Basic | 112 | 112 | 112 | 111 | |||
Diluted | 113 | 113 | 113 | 112 | |||
Quest Diagnostics Incorporated and Subsidiaries Consolidated Balance Sheets September 30, 2025 and December 31, 2024 (in millions, except per share data) (unaudited) | |||
September 30, | December 31, | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 432 | $ 549 | |
Accounts receivable, net | 1,456 | 1,304 | |
Inventories | 186 | 188 | |
Prepaid expenses and other current assets | 333 | 351 | |
Total current assets | 2,407 | 2,392 | |
Property, plant and equipment, net | 2,145 | 2,113 | |
Operating lease right-of-use assets | 649 | 651 | |
Goodwill | 8,901 | 8,856 | |
Intangible assets, net | 1,662 | 1,763 | |
Investments in equity method investees | 137 | 123 | |
Other assets | 296 | 255 | |
Total assets | $ 16,197 | $ 16,153 | |
Liabilities and Stockholders' Equity | |||
Current liabilities: | |||
Accounts payable and accrued expenses | $ 1,457 | $ 1,394 | |
Current portion of long-term debt | 504 | 602 | |
Current portion of long-term operating lease liabilities | 173 | 173 | |
Total current liabilities | 2,134 | 2,169 | |
Long-term debt | 5,171 | 5,615 | |
Long-term operating lease liabilities | 534 | 535 | |
Other liabilities | 982 | 938 | |
Redeemable noncontrolling interest | 81 | 83 | |
Stockholders' equity: | |||
Quest Diagnostics stockholders' equity: | |||
Common stock, par value $0.01 per share; 600 shares authorized as of both September 30, 2025 | 2 | 2 | |
Additional paid-in capital | 2,355 | 2,361 | |
Retained earnings | 9,837 | 9,360 | |
Accumulated other comprehensive loss | (40) | (88) | |
Treasury stock, at cost; 51 shares as of both September 30, 2025 and December 31, 2024 | (4,896) | (4,857) | |
Total Quest Diagnostics stockholders' equity | 7,258 | 6,778 | |
Noncontrolling interests | 37 | 35 | |
Total stockholders' equity | 7,295 | 6,813 | |
Total liabilities and stockholders' equity | $ 16,197 | $ 16,153 | |
Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2025 and 2024 (in millions) (unaudited) | |||
Nine Months Ended | |||
2025 | 2024 | ||
Cash flows from operating activities: | |||
Net income | $ 790 | $ 685 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 425 | 358 | |
Provision for credit losses | 2 | 4 | |
Deferred income tax expense (benefit) | 118 | (21) | |
Stock-based compensation expense | 63 | 61 | |
Other, net | 37 | 17 | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (153) | (140) | |
Accounts payable and accrued expenses | 113 | (102) | |
Income taxes payable | (1) | 31 | |
Other assets and liabilities, net | 27 | (23) | |
Net cash provided by operating activities | 1,421 | 870 | |
Cash flows from investing activities: | |||
Business acquisitions, net of cash acquired | (51) | (1,781) | |
Capital expenditures | (369) | (302) | |
Other investing activities, net | (20) | 37 | |
Net cash used in investing activities | (440) | (2,046) | |
Cash flows from financing activities: | |||
Proceeds from borrowings | 410 | 1,846 | |
Repayments of debt | (1,011) | (302) | |
Purchases of treasury stock | (150) | — | |
Exercise of stock options | 61 | 52 | |
Employee payroll tax withholdings on stock issued under stock-based compensation plans | (44) | (24) | |
Dividends paid | (263) | (247) | |
Distributions to noncontrolling interest partners | (43) | (35) | |
Other financing activities, net | (61) | (36) | |
Net cash (used in) provided by financing activities | (1,101) | 1,254 | |
Effect of exchange rate changes on cash and cash equivalents and restricted cash | 3 | — | |
Net change in cash and cash equivalents and restricted cash | (117) | 78 | |
Cash and cash equivalents and restricted cash, beginning of period | 549 | 686 | |
Cash and cash equivalents and restricted cash, end of period | $ 432 | $ 764 | |
Cash paid during the period for: | |||
Interest | $ 167 | $ 167 | |
Income taxes | $ 112 | $ 179 | |
Notes to Financial Tables
1) The computation of basic and diluted earnings per common share is as follows: | |||||||
Three Months Ended | Nine Months Ended | ||||||
2025 | 2024 | 2025 | 2024 | ||||
(in millions, except per share data) | |||||||
Amounts attributable to Quest Diagnostics' common stockholders: | |||||||
Net income attributable to Quest Diagnostics | $ 245 | $ 226 | $ 747 | $ 649 | |||
Less: earnings allocated to participating securities | 2 | 1 | 4 | 3 | |||
Earnings available to Quest Diagnostics' common stockholders - basic and diluted | $ 243 | $ 225 | $ 743 | $ 646 | |||
Weighted average common shares outstanding - basic | 112 | 112 | 112 | 111 | |||
Effect of dilutive securities: | |||||||
Stock options and performance share units | 1 | 1 | 1 | 1 | |||
Weighted average common shares outstanding - diluted | 113 | 113 | 113 | 112 | |||
Earnings per share attributable to Quest Diagnostics' common stockholders: | |||||||
Basic | $ 2.18 | $ 2.01 | $ 6.66 | $ 5.80 | |||
Diluted | $ 2.16 | $ 1.99 | $ 6.57 | $ 5.74 | |||
2) The following tables reconcile reported GAAP results to non-GAAP adjusted results: | |||||||||||
Three Months Ended September 30, 2025 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 386 | 13.7 % | $ (77) | $ 8 | $ 245 | $ 2.16 | |||||
Restructuring and integration charges (a) | 11 | 0.4 | (2) | — | 9 | 0.07 | |||||
Other charges (b) | 22 | 0.8 | (6) | — | 16 | 0.15 | |||||
Amortization expense | 39 | 1.4 | (10) | — | 29 | 0.25 | |||||
ETB | — | — | (3) | — | (3) | (0.03) | |||||
As adjusted | $ 458 | 16.3 % | $ (98) | $ 8 | $ 296 | $ 2.60 | |||||
Nine Months Ended September 30, 2025 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 1,170 | 14.2 % | $ (233) | $ 35 | $ 747 | $ 6.57 | |||||
Restructuring and integration charges (a) | 37 | 0.5 | (9) | — | 28 | 0.24 | |||||
Other charges (b) | 52 | 0.6 | (12) | — | 40 | 0.36 | |||||
Gains and losses on investments (c) | — | — | 1 | (1) | (2) | (0.01) | |||||
Other gains (d) | (46) | (0.5) | 14 | (8) | (40) | (0.36) | |||||
Amortization expense | 117 | 1.4 | (30) | — | 87 | 0.76 | |||||
ETB | — | — | (15) | — | (15) | (0.13) | |||||
As adjusted | $ 1,330 | 16.2 % | $ (284) | $ 26 | $ 845 | $ 7.43 | |||||
Three Months Ended September 30, 2024 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 330 | 13.3 % | $ (65) | $ 6 | $ 226 | $ 1.99 | |||||
Restructuring and integration charges (a) | 18 | 0.7 | (3) | — | 15 | 0.13 | |||||
Other charges (b) | 5 | 0.2 | — | — | 4 | 0.04 | |||||
Gains and losses on investments (c) | — | — | — | 2 | 2 | 0.02 | |||||
Other gains (d) | — | — | 2 | — | (6) | (0.06) | |||||
Amortization expense | 32 | 1.3 | (8) | — | 24 | 0.21 | |||||
ETB | — | — | (3) | — | (3) | (0.03) | |||||
As adjusted | $ 385 | 15.5 % | $ (77) | $ 8 | $ 262 | $ 2.30 | |||||
Nine Months Ended September 30, 2024 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 985 | 13.6 % | $ (205) | $ 14 | $ 649 | $ 5.74 | |||||
Restructuring and integration charges (a) | 45 | 0.6 | (10) | — | 35 | 0.31 | |||||
Other charges (b) | 12 | 0.2 | — | — | 11 | 0.10 | |||||
Gains and losses on investments (c) | — | — | (3) | 11 | 8 | 0.07 | |||||
Other gains (d) | — | — | 2 | — | (6) | (0.06) | |||||
Amortization expense | 90 | 1.2 | (23) | — | 67 | 0.59 | |||||
ETB | — | — | (6) | — | (6) | (0.05) | |||||
As adjusted | $ 1,132 | 15.6 % | $ (245) | $ 25 | $ 758 | $ 6.70 | |||||
(a) | For each of the three and nine months ended September 30, 2025 and 2024, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations: | |||||||
Three Months Ended | Nine Months Ended | ||||||
2025 | 2024 | 2025 | 2024 | ||||
(dollars in millions) | |||||||
Cost of services | $ 1 | $ 5 | $ 8 | $ 19 | |||
Selling, general and administrative | 10 | 15 | 29 | 28 | |||
Other operating expense, net | — | (2) | — | (2) | |||
Operating income | $ 11 | $ 18 | $ 37 | $ 45 | |||
(b) | The pre-tax impacts for both the three and nine months ended September 30, 2025 include a $15 million charge to earnings related to legal matters. Additionally, the three and nine months ended September 30, 2025 include impairment charges of $5 million and $29 million, respectively, on certain long-lived assets related to the exit of a business. Also, each of the three and nine months ended September 30, 2025 and 2024 include losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions. The following table summarizes the pre-tax impact of these other charges on our consolidated statements of operations: | |||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2025 | 2024 | 2025 | 2024 | ||||
(dollars in millions) | |||||||
Selling, general and administrative | $ — | $ 1 | $ — | $ 2 | |||
Other operating expense, net | 22 | 4 | 52 | 10 | |||
Operating income | $ 22 | $ 5 | $ 52 | $ 12 | |||
(c) | For each of the three and nine months ended September 30, 2025 and 2024, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes. | |||||||
(d) | The nine months ended September 30, 2025 include a $46 million pre-tax gain, recorded in other operating expense, net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") associated with the retention of employees. Additionally, the nine months ended September 30, 2025 include a pre-tax gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease. For the three and nine months ended September 30, 2024, other income, net includes a non-recurring pre-tax gain associated with a foreign exchange forward contract utilized in conjunction with an acquisition. The following table summarizes the pre-tax impact of these other gains on our consolidated statements of operations: | |||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2025 | 2024 | 2025 | 2024 | ||||
(dollars in millions) | |||||||
Other operating expense, net | $ — | $ — | $ 46 | $ — | |||
Other income, net | $ — | $ 8 | $ — | $ 8 | |||
Equity in earnings of equity method investees, net of taxes | $ — | $ — | $ 8 | $ — | |||
(e) | For restructuring and integration charges, other gains/charges, gains and losses on investments and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2025 and 2024. No income tax impact was recorded on gains/losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisition. |
3) | For both the three and nine months ended September 30, 2025, we repurchased 0.9 million shares of our common stock for $150 million. As of September 30, 2025, $0.7 billion remained available under our share repurchase authorization. |
4) | The outlook for adjusted diluted EPS represents management's estimates for the full year 2025 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2025. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2025 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS: |
Low | High | ||
Diluted EPS | $ 8.58 | $ 8.66 | |
Restructuring and integration charges (a) | 0.30 | 0.30 | |
Amortization expense (b) | 1.02 | 1.02 | |
Other charges (c) | 0.39 | 0.39 | |
Other gains (d) | (0.36) | (0.36) | |
Gains and losses on investments (e) | (0.01) | (0.01) | |
ETB | (0.16) | (0.16) | |
Adjusted diluted EPS | $ 9.76 | $ 9.84 |
(a) | Represents estimated pre-tax charges of $45 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%. | |||||||
(b) | Represents estimated pre-tax amortization expenses of $154 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%. | |||||||
(c) | Includes a $29 million pre-tax impairment charge on certain long-lived assets related to the exit of a business and a $15 million charge to earnings related to legal matters. Additionally, includes estimated pre-tax net charges of $11 million associated with the estimated change in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax impacts were recorded on the changes associated with the contingent consideration accrual. Income tax benefits on the other charges were calculated using a combined statutory income tax rate of 25.5%. | |||||||
(d) | Includes a pre-tax gain of $46 million related to a payroll tax credit under the CARES Act associated with the retention of employees. Additionally, includes a non-recurring pre-tax gain of $8 million related to a lease. Income tax impacts were calculated using a combined statutory income tax rate of 25.5%. | |||||||
(e) | Income tax impacts were calculated using a combined statutory income tax rate of 25.5%. |
| Last Trade: | US$185.51 |
| Daily Change: | -4.90 -2.57 |
| Daily Volume: | 1,457,552 |
| Market Cap: | US$20.740B |
September 23, 2025 September 18, 2025 September 04, 2025 September 02, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
